Page 3 - Pharma Industry

Tariff uncertainties may spur rise in third-party pharma manufacturing

Analysts say Indian drugmakers may lean on CDMOs, US plants and diversification to safeguard high-value products as Trump's 100% tariff threat looms over patented drugs

US tariffs threaten $3.1 bn Singapore pharma exports, trade talks continue

This is a concern for Singapore as pharmaceuticals form around 13% of all Singapore exports to the U.S., said Gan

Indian pharma firms likely to dodge immediate impact of Trump's tariff

Trump's 100% tariffs on branded drugs will spare Indian generics, though analysts see exposure for Sun Pharma, Biocon and Aurobindo, with Jubilant Pharmova set to benefit

Asia stocks slide as Trump slaps new pharma tariffs, Fed cut bets recede

Shares of pharmaceutical companies across Asia tumbled in the aftermath, with Japan's Topix pharmaceutical index last down 1.2 per cent, while Hong Kong-listed innovative drug index fell 2 per cent

Trump announces 100% tariff on pharma imports; duties on trucks, furniture

Trump said the new tariffs would not apply to companies that are actively building pharmaceutical manufacturing facilities in the US

Indian drugmakers gear up for ₹600-800 cr insulin pen market post-Novo exit

Novo Nordisk to phase out insulin pens and cartridges in India; Eris, Wockhardt and Lupin prepare to capture Rs 600-800 crore market opportunity from FY26 onwards

Indian pharma sector revenue growth to ease to 7-9% in FY26: Crisil

Crisil projects India pharma growth at 7-9% in FY26 as exports to regulated markets slow after a US high base while domestic sales benefit from tax cuts and launches

Monin invests ₹350 crore in Hyderabad plant, eyes ₹450 crore turnover

Germain Araud, managing director of Monin India, said the facility will span 40 acres and is expected to be operational by the second quarter of 2026

USFDA cautions doctors on acetaminophen use in pregnancy, cites risks

The US drug regulator flagged concerns over acetaminophen use in pregnancy, citing studies linking it to autism and ADHD, while noting no proven causal relationship

Domestic pharma firms expected to post 7-9% revenue growth in FY26: Icra

Revenue of leading domestic pharmaceutical companies is set to expand by 7-9 per cent in the current fiscal even as global headwinds and regulatory uncertainties cast a shadow over its largest export market, the US, as per rating firm Icra. Revenue for the sample set of companies is projected to expand by 7-9 per cent in FY2026, supported by 8-10 per cent growth in the domestic market and 10-12 per cent growth in Europe, it stated. However, performance in the US market is expected to moderate, with year-on-year growth slowing to 3-5 per cent, from nearly 10 per cent in FY2025, Icra said. The operating profit margins (OPM) of ICRA's sample entities are expected to remain resilient at 24-25 per cent in FY2026, broadly in line with 24.6 per cent in FY2025, aided by favourable raw material prices, improved operating leverage, and a rising share of speciality products, it added. Research and Development (R&D) spending is projected to remain steady at 6-7 per cent of revenues, with ...

Indian pharma faces US revenue slowdown amid scrutiny, tariffs: ICRA

ICRA projects Indian pharma firms' US revenue growth to slow due to price erosion, USFDA scrutiny and tariff risks, while high dependence on Chinese APIs persists despite PLI

Lupin gets USFDA nod for generic cancer drug Lenalidomide capsules

Lupin has received USFDA approval for generic Lenalidomide capsules in six strengths, adding to competition in the US oncology market for Bristol-Myers Squibb's Revlimid

Mankind joins hands with OpenAI to institutionalise AI in operations

"GPT-powered dashboards will be used to provide real-time, data-driven insights across R&D, supply chain and commercial operations," a company executive told Business Standard

NPPA asks pharma firms to pass on GST rate cut benefits from Sept 22

The National Pharmaceutical Pricing Authority has asked pharmaceutical companies and medical device makers to pass on the benefit of reduced GST rates to consumers with effect from September 22. "The benefit of reduction in GST rates shall be passed on to consumers/patients effective from September 22, 2025. All the manufacturers /marketing companies selling drugs/formulations shall revise theP of drugs/formulations (including medical devices) accordingly, with effect from September 22," the authority said in an order. The manufacturer and marketing companies shall issue a revised price list or supplementary price list to the dealers, retailers, state drug controllers and the government, reflecting the revised GST rates and revisedP, the National Pharmaceutical Pricing Authority (NPPA) stated. Manufacturer and marketing companies shall take immediate measures to sensitise dealers, retailers, and consumers about the reduction in GST rates through all possible channels of communicatio

NPPA asks pharma, medtech firms to cut prices after GST rate reduction

NPPA directs pharma and medical device makers to revise MRPs after GST cut to 5 per cent, while making relabelling of old stock voluntary subject to compliance

Biocon expands US footprint with new Cranbury manufacturing facility

Biocon inaugurated its first US manufacturing facility in Cranbury through Biocon Generics, expanding its global footprint and strengthening supply chains for essential therapies

Shukra Pharma enters into pan-India distribution pact with Wockhardt

Shukra Pharmaceuticals on Wednesday said it has entered into a strategic non-exclusive Pan-India distribution arrangement with Wockhardt Ltd. The authorization is effective from September 9, 2025 and is valid until March 2026, an exchange filing said. The products include advanced anti-infective formulations and antibiotics developed to combat critical infections. The mandate includes distribution and management of products across all ESIC/ESIS hospitals and Defence/AFMSD/DGAFMS units throughout India, the filing said. "This collaboration further strengthens Shukra Pharmaceuticals presence in institutional and government healthcare networks across India, enhancing revenue visibility and operational footprint," the company said. Shukra Pharmaceuticals Limited is engaged in manufacturing and marketing pharmaceutical products as well as laboratory testing.

Sun Pharma stock concerns may be overstated as domestic growth holds

Analysts say Sun Pharma's stock concerns are overdone, with strong domestic growth, broad-based chronic portfolio gains and resilient Q1FY26 earnings offsetting US market worries

Glenmark gains 3% on $700 mn upfront payment from AbbVie licensing deal

Glenmark shares rose 3% after confirming receipt of $700 million from AbbVie under a global licensing deal for ISB 2001, with milestone payments of up to $1.2 billion

Strides enters into product partnership with Kenox for nasal spray

Strides Pharma Science Ltd on Monday said its Singapore-based subsidiary has entered into a strategic product development partnership with Kenox Pharmaceuticals Inc, which will strengthen the pipeline of nasal spray products across diverse therapeutic areas. Strides Pharma Global Pte, Singapore will collaborate with Kenox on the development and filing of multiple nasal spray products for the US market across diverse therapeutic indications, a joint statement said. The collaboration aims to accelerate affordable, high-quality medicines for patients in the US. However, it also mentioned that specific product details remain confidential at this stage. Kenox is a contract development and manufacturing company specialising in Orally Inhaled and Nasal Drug Products (OINDPs). Strides Pharma Science Executive Director Business Development Aditya Kumar said: "Weannounce this partnership with Kenox, a company that brings deep technical expertise in the OINDP space. Nasal sprays have ...